Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 6Unknown 2Terminated 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 22Lymphoma, Large B-Cell, Diffuse 16Recurrence 7Neoplasms, Plasma Cell 5Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Leukemia, Myeloid, Acute 4Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, B-Cell 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Paraproteinemias 2Neoplasms by Histologic Type 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Hematologic Diseases 2Colorectal Neoplasms 2Blood Protein Disorders 2Sezary Syndrome 1Renal Insufficiency 1Neuroblastoma 1Mycosis Fungoides 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Dexamethasone 3isatuximab 2Lenalidomide 2Cyclophosphamide 2pomalidomide 1fludarabine phosphate 1fludarabine 1daratumumab 1Watchful Waiting 1Vorinostat 1Vincristine 1Specimen Handling 1Rituximab 1Ranitidine 1R-CHOP protocol 1Prednisone 1Interviews as Topic 1Injections 1Histone Deacetylase Inhibitors 1Filgrastim 1Exercise 1Doxorubicin 1Diphenhydramine 1Data Collection 1Bortezomib 1Acetaminophen 1AC protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Hematologic Diseases × Lenalidomide × Clear all
NCT05280275 2023-12-01

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

Hellenic Society of Hematology

Phase 1/2 Unknown
36 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Hellenic Society of Hematology

Phase 2 Unknown
51 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡